Cargando…

One year later: The case of tocilizumab in COVID-19

Detalles Bibliográficos
Autores principales:	Campochiaro, Corrado, Tomelleri, Alessandro, Matucci-Cerinic, Marco, Dagna, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Federation of Internal Medicine. Published by Elsevier B.V. 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536517/ https://www.ncbi.nlm.nih.gov/pubmed/34711474 http://dx.doi.org/10.1016/j.ejim.2021.10.024

Ejemplares similares

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
por: De Luca, Giacomo, et al.
Publicado: (2021)

Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey
por: Tomelleri, Alessandro, et al.
Publicado: (2020)

Successful use of ixekizumab for glucocorticoid-free remission maintenance in giant cell arteritis
por: Tomelleri, Alessandro, et al.
Publicado: (2022)

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Adult-onset Still’s disease complicated by Guillain-Barré syndrome
por: Farina, Nicola, et al.
Publicado: (2023)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
por: Cavalli, Giulio, et al.
Publicado: (2020)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
por: Tomelleri, Alessandro, et al.
Publicado: (2018)

COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic
por: Denton, Christopher P, et al.
Publicado: (2020)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Multimodal Chorioretinal Imaging in Erdheim-Chester Disease
por: Sacconi, Riccardo, et al.
Publicado: (2020)

The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis
por: Farina, Nicola, et al.
Publicado: (2022)

Pneumothorax/pneumomediastinum in non-intubated COVID-19 patients: Differences between first and second Italian pandemic wave
por: Palumbo, Diego, et al.
Publicado: (2021)

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Cardiovascular involvement in Erdheim–Chester diseases is associated with myocardial fibrosis and atrial dysfunction
por: Palmisano, Anna, et al.
Publicado: (2023)

The Contribution of Imaging Beyond Clinical Diagnosis, the Ochronosis and Synovio-entheseal Complex Examples
por: Pacini, Giovanni, et al.
Publicado: (2022)

The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress
por: Orlandi, Martina, et al.
Publicado: (2020)

A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)
por: Campochiaro, Corrado, et al.
Publicado: (2021)

Time for tocilizumab in COVID-19?
por: Butler, Ethan, et al.
Publicado: (2021)

The COVID-19 pandemic: one year later – an occupational perspective
Publicado: (2021)

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

Interstitial pneumonia with autoimmune features: a new classification still on the move
por: Cavagna, Lorenzo, et al.
Publicado: (2018)

Cyclophosphamide in systemic sclerosis: still in search of a 'real life' scenario
por: Miniati, Irene, et al.
Publicado: (2009)

The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?
por: Manetti, Mirko, et al.
Publicado: (2016)

Treatment of systemic sclerosis: is there any hope for the future?
por: Allanore, Yannick, et al.
Publicado: (2016)

Tocilizumab in COVID-19: Is the Temptation Worthwhile?
por: Gupta, Sachin, et al.
Publicado: (2021)

The journal: one year later
por: Nath, Rahul K
Publicado: (2007)

Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation
por: TUFAN, Abdurrahman, et al.
Publicado: (2021)

Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials
por: Belletti, Alessandro, et al.
Publicado: (2021)

Estimation Statistics, One Year Later
por: Bernard, Christophe
Publicado: (2021)

Tocilizumab for Covid-19 — The Ongoing Search for Effective Therapies
por: Huang, Edmund, et al.
Publicado: (2020)

Cardiac magnetic resonance findings in acute and post‐acute COVID‐19 patients with suspected myocarditis
por: Palmisano, Anna, et al.
Publicado: (2022)

Myocarditis: An Interleukin-1-Mediated Disease?
por: De Luca, Giacomo, et al.
Publicado: (2018)

Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
por: Cavalli, Giulio, et al.
Publicado: (2021)

COVID-19 : encore une place pour le tocilizumab ?
por: Richier, Q., et al.
Publicado: (2021)

European Journal of Psychotraumatology: One year later…
por: Olff, Miranda, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_l3lv9pkl8p006hc1s0dlirpem0